Pharmacosurveillance and safety of the leukotriene receptor antagonist (LTRA), montelukast

Clinical and Experimental Allergy Reviews

Volumn 1, Issue 3, 2001, Pages 300-304

  Biswas, P ^a   Wilton, L ^a   Pearce, G ^a   Freemantle, S ^a   Shakir, S ^a   Mann, R D ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1042275189     PISSN: 14729725     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-9725.2001.t01-1-00016.x     Document Type: Article

References (4)

1. Rawlins MD, Jefferys DB. Study of United Kingdom product licence applications containing new active substances, 1987-9. Br Med J 1991; 302:223-5.
2. Mann RD. Editorial: the background to changing consent requirements regarding the use of recorded data for drug safety surveillance. Pharmacoepidemiol Drug Safety 2000; 9:181-6.
3. Mann RD. Prescription-event monitoring. In: Strom BL, ed. Pharmacoepidemiology, 3rd edn. eds. Chichester, UK: Wiley & Sons, 2000:231-46.
4. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions. Retrospective analysis of 58 Prescription-event Monitoring Cohort Studies. Pharmacoepidemiol Drug Safety 1999; 8:179-89.